FilingsTodayRoivant Sciences
At a glance
Roivant Sciences reported 2025 revenue of $8.3M, down 71.6% from $29.1M in 2024. Over 4 years since 2021 ($55.3M), that is a decline of about 37.8% a year. Operating margin was -6235.7%, down from -2444.8% in 2021. Revenue peaked in 2021 at $55.3M. The company posted a loss in 2021, 2022, 2024 and 2025.
In the last 12 months 11 insiders reported 0 open-market purchases and 40 sales ($646.6M). 20 of the sales were made under pre-arranged 10b5-1 plans. The largest was a sale of $82M by President and Vant Chair Frank Torti on Feb 23, 2026.
Roivant Sciences filed 14 current reports (Form 8-K) in the last 12 months, most often for regulation fd disclosure (5), results of operations (5), material agreement (2) and shareholder vote results (1). It reported a material agreement or a completed acquisition or disposal 2 times.
1 of the 20 investors tracked here held Roivant Sciences at the last quarter end, worth $221.9M combined. It is the largest weight for Viking Global Investors (0.6% of its portfolio). Reduced: Viking Global Investors.
Annual results
| Year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Net income | -$845.3M | -$1.01B | $4.35B | -$172M | -$299.8M |
| Diluted EPS | $-1.26 | $-1.42 | $5.23 | $-0.24 | $-0.54 |
Fiscal year ends Mar 31 · incorporated in D0
Tracked investors holding (13F)
Weight is the share of each investor's portfolio, as of the quarter end.
Current reports (8-K, last 12 months)
Insider open-market trades (last 12 months)
Source: SEC EDGAR. How figures are combined